Absci to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Absci (Nasdaq: ABSI) announced participation in two upcoming investor conferences in June 2026. Management will present at the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, with live and archived webcasts on its investor relations site.
Positive
- None.
Negative
- None.
News Market Reaction – ABSI
In the May 20 session, ABSI gained 6.91%, reflecting a notable positive market reaction. Argus tracked a peak move of +3.5% during that session. Our momentum scanner triggered 22 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
VANCOUVER, Wash. and NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will be participating in the following upcoming investor conferences:
- 2026 Jefferies Global Healthcare Conference (New York, NY)
Presentation on Wednesday, June 3rd at 7:35 a.m. Eastern Time / 4:35 a.m. Pacific Time
- Goldman Sachs 47th Annual Global Healthcare Conference (Miami, FL)
Presentation on Tuesday, June 9th at 3:20 p.m. Eastern Time / 12:20 p.m. Pacific Time
Interested parties may access live and archived webcasts of the presentations on the company’s investor relations website at: investors.absci.com.
About Absci
Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics including ABS-201™, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern hair-loss. ABS-201 is also being investigated as a potential “best-in-class” therapeutic for endometriosis, a condition with significant unmet medical need and market potential. Absci is headquartered in Vancouver, WA, with AI Research Labs in New York City and Serbia, and an Innovation Center in Switzerland. Learn more at www.absci.com or follow us on LinkedIn (@absci), X (@Abscibio) and YouTube.
Absci® standard character mark, ABS-201™, and Integrated Drug Creation™ are trademarks and registered trademarks of Absci Corporation.
Investor Contact
Alexander D.H. Khan
Corporate Vice President, Head of Investor Relations
investors@absci.com
Media Contact
press@absci.com
